3 models fit Verisk Analytics Inc. Common Stock and they disagree: 1 of 3 land within 15% of the average. The price is above every model.
Two or more of our models back this value.
Large premium(i)Silver64
Valued as a cyclical company: P/E comparison, EV/EBITDA comparison, Discounted cash flow, and Graham number.
ACCE opinionVerisk Analytics Inc. Common Stock (VRSK)
Fair value (3 models)
$130
ACCE price target
$172
Rating
Overvalued
Horizon
12 months
Fair value published on 19 Oct 2026, 19:04 CEST; previously $134 since 15 Oct 2026, 00:00 CEST.
ACCE price target published on 25 Sept 2026, 00:00 CEST.
Rating published on 19 Oct 2026, 19:04 CEST.
Price used: $196 at the close on 23 Oct 2026, 22:00 CEST.
Models: Discounted cash flow, P/E comparison, and EV/EBITDA comparison.
Fair value: the average of the applicable valuation models (discounted cash flow, multiples, residual income, dividend discount, shareholder yield), each run on the latest financial statements and the market price shown. Opinion columns (fair value, target, rating) are shown apart from the data. Full methodology: acceinvestments.com/data/how-we-value-stocks
Conflicts of interest: The author holds no personal position in this security. General statement
Produced by ACCE Investments (acceinvestments.com)
Data
Price vs fair value
50.2% above
-33.4% to fair value
ACCE score
56
out of 100
Analysts
58% buy
19 covering
P/E
31.2x
forward 20.1x
1-year return
-16.6%
Dividend yield
0.99%
Verisk Analytics Inc. Common Stock in four questions
Plain answers, details below
Free accounts get 5 full stock pages a month, including the four answers.
Overview
ACCE thesis
Verisk sells the data and analytics that insurers use to price and underwrite property and casualty risk, including ISO loss costs, claims analytics, and catastrophe modeling, and it has spent years layering subscription products on top of that proprietary database. Its moat rests on being embedded in insurers' underwriting and claims workflows, which makes switching costs high and explains a 70.2% gross margin and 45.1% operating margin. The near-term driver is the steady shift of its revenue toward recurring analytics subscriptions, with 4.4% revenue growth showing the base is still compounding without much help from acquisitions. At a 27.3x trailing P/E and 20.4x forward P/E, the stock is pricing in meaningful earnings growth, and a 43.8% ROE suggests the business converts that growth into returns efficiently. The score of 51/100 and absence from major indices mean the quantitative screen does not yet flag it as compelling, so the case needs a deeper look at organic growth durability and the multiple's sensitivity to insurance-cycle slowdowns.